Research programme: immunotherapeutic vaccines - Scancell

Drug Profile

Research programme: immunotherapeutic vaccines - Scancell

Alternative Names: Modi-1; PAP vaccine - Scancell; PAP-114; SCIB-2; SCMod 1

Latest Information Update: 21 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scancell
  • Developer Karolinska Institute; Scancell
  • Class Cancer vaccines; DNA vaccines; Peptide vaccines; Protein-vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Rheumatoid arthritis
  • Discontinued Infections

Most Recent Events

  • 15 Feb 2018 Scancell and ISA Pharmaceuticals enter into licensing and collaboration agreement to use ISA’s AMPLIVANT® adjuvant technology
  • 15 Feb 2018 Scancell plans a clinical trial in Modi-1 for Cancer in first half of 2019
  • 09 Feb 2018 Scancell files patent applications for Moditope® immunotherapy platform in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top